Larimar Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$172.5 | -$90.9 | -$41.8 | -$36.5 | -$50.5 |
| Net income | -$165.7 | -$80.6 | -$36.9 | -$35.4 | -$50.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$113.3 | -$71.3 | -$33.6 | -$27.7 | -$42.4 |
Shares outstanding 103.9M · Free float 84.6%
Annual filing data through FY ended December 31, 2025; float as of October 11, 2026.